For the driver-negative NSCLC, the immune checkpoint inhibitors (ICIs), which include anti-programmed death-1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte associated protein 4 (anti-CTLA-4) agents have become the treatment cornerstones [4]. Here, CTLA4 is linked to non-small cell lung carcinoma.